Innovations and challenges in melanoma: Summary statement from the first Cambridge conference

被引:10
作者
Atkins, MB
Elder, DE
Essner, R
Flaherty, KT
Gajewski, TF
Haluska, FG
Hwu, P
Keilholz, U
Kirkwood, JM
Mier, JW
Ross, MI
Slingluff, CL
Sondak, VK
Sosman, JA
Weinstock, MA
King, L
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[4] John Wayne Canc Inst, Santa Monica, CA USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Free Univ Berlin, Charite, D-1000 Berlin, Germany
[8] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[9] Univ Virginia Hlth Syst, Charlottesville, VA USA
[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[11] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[12] Brown Univ, Providence, RI 02912 USA
[13] InforMEDical Commun Inc, Carlisle, MA USA
关键词
D O I
10.1158/1078-0432.CCR-05-2560
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Innovations and Challenges in Melanoma, chaired by Michael Atkins and cochaired by Ulrich Keilholz, John Kirkwood, and Jeffrey Sosman, was held July 15 to 16, 2005, in Cambridge, Massachusetts. The conference brought together leading experts in the fields of cancer research, medical oncology, surgical oncology, anatomic pathology, dermatology, and immunotherapy who wished to advance the field of melanoma treatment by exchanging information and perspectives regarding recent advances and recommendations for further study. The conference proceedings published in this educational supplement to Clinical Cancer Research are intended to provide timely information and recommendations on how genetics, biology, and data information can enhance our understanding of melanoma biology and help inform the use of therapies for this disease.
引用
收藏
页码:2291S / 2296S
页数:6
相关论文
共 38 条
[1]  
AHMAD T, 2004, J CLIN ONCOL, V22, P7506
[2]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[3]   AN INVARIANT V-ALPHA-24-J-ALPHA-Q/V-BETA-11 T-CELL RECEPTOR IS EXPRESSED IN ALL INDIVIDUALS BY CLONALLY EXPANDED CD4-8- T-CELLS [J].
DELLABONA, P ;
PADOVAN, E ;
CASORATI, G ;
BROCKHAUS, M ;
LANZAVECCHIA, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) :1171-1176
[4]  
DiPaola RS, 1997, CANCER GENE THER, V4, P176
[5]  
Eton O, 2004, J CLIN ONCOL, V22, p717S
[6]   Cutting edge: A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses [J].
Exley, MA ;
Tahir, SMA ;
Cheng, O ;
Shaulov, A ;
Joyce, R ;
Avigan, D ;
Sackstein, R ;
Balk, SP .
JOURNAL OF IMMUNOLOGY, 2001, 167 (10) :5531-5534
[7]  
Flaherty KT, 2004, J CLIN ONCOL, V22, p711S
[8]   EARLY DETECTION OF MALIGNANT-MELANOMA - THE ROLE OF PHYSICIAN EXAMINATION AND SELF-EXAMINATION OF THE SKIN [J].
FRIEDMAN, RJ ;
RIGEL, DS ;
KOPF, AW .
CA-A CANCER JOURNAL FOR CLINICIANS, 1985, 35 (03) :130-151
[9]   Severe and selective deficiency of interferon-γ-producing invariant natural killer T cells in patients with myelodysplastic syndromes [J].
Fujii, S ;
Shimizu, K ;
Klimek, V ;
Geller, MD ;
Nimer, SD ;
Dhodapkar, MV .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) :617-622
[10]   Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate [J].
Furuhashi, M ;
Sjöblom, T ;
Abramsson, A ;
Ellingsen, J ;
Micke, P ;
Li, H ;
Bergsten-Folestad, E ;
Eriksson, U ;
Heuchel, R ;
Betsholtz, C ;
Heldin, CH ;
Östman, A .
CANCER RESEARCH, 2004, 64 (08) :2725-2733